Ziprasidone may increase the sedative activities of Metyrosine. The metabolism of Brinzolamide can be decreased when combined with Ziprasidone. The therapeutic efficacy of Gliclazide can be decreased when used in combination with Ziprasidone. The metabolism of Antipyrine can be decreased when combined with Ziprasidone. The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Ziprasidone. The therapeutic efficacy of Pramlintide can be decreased when used in combination with Ziprasidone. Tolterodine may increase the QTc-prolonging activities of Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl loflazepate. The metabolism of Seratrodast can be decreased when combined with Ziprasidone. The metabolism of Methadone can be decreased when combined with Ziprasidone. The metabolism of Ajmaline can be decreased when combined with Ziprasidone. The metabolism of Canagliflozin can be decreased when combined with Ziprasidone. The serum concentration of Doxorubicin can be increased when it is combined with Ziprasidone. The serum concentration of Ziprasidone can be decreased when it is combined with Siltuximab. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloroprocaine. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ziconotide. The serum concentration of Apixaban can be increased when it is combined with Ziprasidone. The metabolism of Cocaine can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Procaine. The metabolism of Ziprasidone can be decreased when combined with Clemastine. Vilanterol may increase the QTc-prolonging activities of Ziprasidone. The metabolism of Methaqualone can be decreased when combined with Ziprasidone. Ziprasidone may decrease the stimulatory activities of Ritobegron. The metabolism of Spiramycin can be decreased when combined with Ziprasidone. The metabolism of Palonosetron can be decreased when combined with Ziprasidone. The therapeutic efficacy of Gliquidone can be decreased when used in combination with Ziprasidone. The metabolism of Morphine can be decreased when combined with Ziprasidone. The metabolism of Albendazole can be decreased when combined with Ziprasidone. The metabolism of Tipranavir can be decreased when combined with Ziprasidone. The metabolism of Loratadine can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fexofenadine. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Amperozide. The metabolism of Verapamil can be decreased when combined with Ziprasidone. Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. The serum concentration of Ziprasidone can be decreased when it is combined with Mitotane. The metabolism of Debrisoquin can be decreased when combined with Ziprasidone. The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Anagrelide. The metabolism of Mebendazole can be decreased when combined with Ziprasidone. The metabolism of Ziprasidone can be decreased when combined with Indinavir. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Enflurane. Lithium may increase the neurotoxic activities of Ziprasidone. The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Normethadone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Loprazolam. The metabolism of Estrone can be decreased when combined with Ziprasidone. The metabolism of Baricitinib can be decreased when combined with Ziprasidone. The serum concentration of Lomitapide can be increased when it is combined with Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Molindone. The metabolism of Enasidenib can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Linezolid is combined with Ziprasidone. The metabolism of Remoxipride can be decreased when combined with Ziprasidone. The metabolism of Propoxyphene napsylate can be decreased when combined with Ziprasidone. The metabolism of Cerivastatin can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dextromoramide. The serum concentration of Ziprasidone can be increased when it is combined with Luliconazole. The metabolism of Bexarotene can be decreased when combined with Ziprasidone. The metabolism of Artemether can be decreased when combined with Ziprasidone. The serum concentration of Ziprasidone can be decreased when it is combined with Dabrafenib. The metabolism of Halothane can be decreased when combined with Ziprasidone. The metabolism of Rucaparib can be decreased when combined with Ziprasidone. The metabolism of Omeprazole can be decreased when combined with Ziprasidone. Promethazine may increase the QTc-prolonging activities of Ziprasidone. The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ziprasidone. The metabolism of Procainamide can be decreased when combined with Ziprasidone. The serum concentration of Ziprasidone can be increased when it is combined with Mifepristone. The metabolism of Ziprasidone can be decreased when combined with Ketoconazole. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fludiazepam. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Alphaprodine. The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Ziprasidone. The metabolism of Ziprasidone can be decreased when combined with Nelfinavir. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lamotrigine. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Trans-2-Phenylcyclopropylamine. The metabolism of Tretinoin can be decreased when combined with Ziprasidone. The metabolism of Chlorzoxazone can be decreased when combined with Ziprasidone. The metabolism of Ziprasidone can be decreased when combined with Boceprevir. The metabolism of Levomilnacipran can be decreased when combined with Ziprasidone. The metabolism of Olopatadine can be decreased when combined with Ziprasidone. The serum concentration of Ivacaftor can be increased when it is combined with Ziprasidone. The metabolism of Roxithromycin can be decreased when combined with Ziprasidone. The metabolism of Nitrendipine can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Milnacipran is combined with Ziprasidone. The metabolism of Vanoxerine can be decreased when combined with Ziprasidone. The serum concentration of Colchicine can be increased when it is combined with Ziprasidone. The metabolism of Levomethadyl Acetate can be decreased when combined with Ziprasidone. The metabolism of Etoposide can be decreased when combined with Ziprasidone. The metabolism of Cortisone acetate can be decreased when combined with Ziprasidone. The metabolism of Argatroban can be decreased when combined with Ziprasidone. The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ziprasidone. The metabolism of Duloxetine can be decreased when combined with Ziprasidone. The serum concentration of Zuclopenthixol can be increased when it is combined with Ziprasidone. The metabolism of Elbasvir can be decreased when combined with Ziprasidone. The therapeutic efficacy of Allicin can be decreased when used in combination with Ziprasidone. The metabolism of Trastuzumab emtansine can be decreased when combined with Ziprasidone. Indacaterol may increase the QTc-prolonging activities of Ziprasidone. The metabolism of Rabeprazole can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Atorvastatin. The metabolism of Imidafenacin can be decreased when combined with Ziprasidone. The metabolism of Zalcitabine can be decreased when combined with Ziprasidone. Isradipine may increase the QTc-prolonging activities of Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tasimelteon. The metabolism of Bedaquiline can be decreased when combined with Ziprasidone. The metabolism of Celecoxib can be decreased when combined with Ziprasidone. The metabolism of Ziprasidone can be decreased when combined with Lobeglitazone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Paliperidone. Metronidazole may increase the QTc-prolonging activities of Ziprasidone. The metabolism of Clevidipine can be decreased when combined with Ziprasidone. The metabolism of Lansoprazole can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Adipiplon. The metabolism of Captopril can be decreased when combined with Ziprasidone. The metabolism of Axitinib can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Butabarbital is combined with Ziprasidone. The metabolism of Promazine can be decreased when combined with Ziprasidone. Atomoxetine may increase the QTc-prolonging activities of Ziprasidone. The serum concentration of Aripiprazole can be increased when it is combined with Ziprasidone. Ziprasidone may decrease the stimulatory activities of Phentermine. Ziprasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. The metabolism of Cinacalcet can be decreased when combined with Ziprasidone. Amantadine may increase the QTc-prolonging activities of Ziprasidone. The metabolism of Quinine can be decreased when combined with Ziprasidone. The metabolism of Ticagrelor can be decreased when combined with Ziprasidone. The metabolism of Doxazosin can be decreased when combined with Ziprasidone. The metabolism of Zafirlukast can be decreased when combined with Ziprasidone. The metabolism of Clopidogrel can be decreased when combined with Ziprasidone. The metabolism of Venetoclax can be decreased when combined with Ziprasidone. The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ziprasidone. The metabolism of Ziprasidone can be decreased when combined with Doxycycline. The metabolism of Fluvastatin can be decreased when combined with Ziprasidone. The therapeutic efficacy of Codeine can be decreased when used in combination with Ziprasidone. The risk or severity of adverse effects can be increased when Ziprasidone is combined with 7-Nitroindazole. The metabolism of Panobinostat can be decreased when combined with Ziprasidone.